Δευτέρα 31 Οκτωβρίου 2016

[Series] Safety and efficacy of biosimilars in oncology

Biosimilars are considered to be one of the solutions to combat the substantially increasing costs of cancer treatment, and its imminent introduction is expected to expand affordability worldwide. However, biosimilar monoclonal antibodies provide many challenges compared with first-generation biosimilars, growth factors, and hormones, because they have shown only a modest clinical effect, and are often used in combination with other more toxic therapies, making it difficult to design studies that allow appropriate efficacy and safety assessments compared with the original products.

http://ift.tt/2eOcdHl

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου